<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors compared the outcome in 100 children (61 boys, 39 girls; median age of 10.1 +/- 3.4 years) with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who underwent either immunosuppressive therapy (IST; n = 70) or hematopoietic stem cell transplantation (HSCT; n = 30) between 1998 and 2007 </plain></SENT>
<SENT sid="1" pm="."><plain>Conditioning regimes for HSCT were a combination of either <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (Cy) with antilymphocyte globulin (ALG) or fludarabine (Flu) with Cy or <z:chebi fb="0" ids="28901">busulfan</z:chebi> (Bu) +/- antithymocyte globulin (ATG) </plain></SENT>
<SENT sid="2" pm="."><plain>Stem cell source was bone marrow in 20 and peripheral blood stem cells (PBSCs) in 10 </plain></SENT>
<SENT sid="3" pm="."><plain>Patients undergoing IST received either equine ALG or ATG in combination with steroids and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Primary engraftment was seen in 25 children (83.3%), with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGvHD) in 5 (16.6%) </plain></SENT>
<SENT sid="5" pm="."><plain>The day 100 transplant-related mortality (TRM) was 30% and at a median follow up of 36 months (range: 6-197), the overall and disease-free survival is 70% </plain></SENT>
<SENT sid="6" pm="."><plain>Among children who received IST, 60 children received ALG while 10 received ATGAM </plain></SENT>
<SENT sid="7" pm="."><plain>Responses were seen in 27 children (43.5%), which was complete (CR) in 12 and partial (PR) in 15 </plain></SENT>
<SENT sid="8" pm="."><plain>At a median follow up of 38 months (range: 1-84), the overall survival is 37.1%, with 81.4% survival among responders and &lt;10% survival among non-responders </plain></SENT>
<SENT sid="9" pm="."><plain>HSCT would be the treatment of choice in children with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who have a human leukocyte antigen (HLA)-matched related donor and is superior to IST in this series from India </plain></SENT>
</text></document>